Home / Companies / Allogene Therapeutics, Inc. / 18 Jun 2025
Allogene Therapeutics, Inc.: meeting of 18 Jun 2025
Votes reported on Form N-PX, item by item
211 Form N-PX filers reported votes at the Allogene Therapeutics, Inc. meeting of 18 Jun 2025. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
3 nominees; 51.9% of reported votes for; 57 filers withheld from or voted against at least one nominee.
396 vote records from 79 filers. 31 of the 79 filers that marked the item either way voted against management.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
290 vote records from 210 filers. 22 of the 201 filers that marked the item either way voted against management. 9 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
132 vote records from 79 filers. 0 of the 79 filers that marked the item either way voted against management.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Auditor |
|---|---|---|---|
| Vanguard | For | For | For |
| BlackRock and iShares | For | For | For |
| Fidelity | For | For | For |
| Dimensional | No report | For | No report |
| State Street and SPDR | Abstain or withhold * | For | For |
| Invesco | For | For | For |
| Equitable | For | For | For |
| Charles Schwab | For | For | For |
| Nuveen and TIAA | For | For | For |
| ProShares and ProFunds | Abstain or withhold * | For | For |
| John Hancock and Manulife | For | For | For |
| Morgan Stanley, Eaton Vance and Calvert | Abstain or withhold * | For | For |
| J.P. Morgan | For | For | For |
| Goldman Sachs | For | For | For |
| WisdomTree | Abstain or withhold * | For | For |
| PGIM and Prudential | Abstain or withhold * | For | For |
| Northern Trust and FlexShares | For | For | For |
| SEI | For | For | For |
| T. Rowe Price | For | For | For |
| Lincoln Financial | For | For | For |
| Voya | Abstain or withhold * | For | For |
| First Trust | No report | Split or no vote | No report |
| Nationwide | For | For | For |
| Victory Capital | Abstain or withhold * | For | For |
| Brighthouse Funds | Abstain or withhold * | For | For |
| Guggenheim and Rydex | Abstain or withhold * | For | For |
| Columbia Threadneedle | For | For | For |
| BNY Mellon | No report | For | No report |
| Principal | No report | For | No report |
| Capital Group and American Funds | For | Against * | For |
| Pacific Life funds | For | For | For |
| Global X | For | For | For |
| Federated Hermes | For | For | For |
| AllianceBernstein | No report | For | No report |
| DWS | Abstain or withhold * | For | For |
| Macquarie and Delaware Funds | Abstain or withhold * | For | For |
| Neuberger Berman | No report | For | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Allogene Therapeutics, Inc. meeting?
211 Form N-PX filers reported votes at the meeting of 18 Jun 2025. On say-on-pay, 22 of 201 voted against management (10.9%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Allogene Therapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Allogene Therapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Allogene Therapeutics, Inc. with a meeting date within three days of 18 Jun 2025. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 23 Sep 2026.